Characteristics of HSCT patients for posttransplant follow-up study
| Characteristics . | No cGVHD, n = 19 . | cGVHD, n = 30 . | |
|---|---|---|---|
| Age at transplant, y | Medium | 51 | 60 |
| Range | 21-69 | 29-71 | |
| Sex, % | F | 12 (63) | 13 (43) |
| M | 7 (37) | 17 (57) | |
| Disease, % | AML/MDS | 12 (63) | 24 (80) |
| Others | 7 (37) | 6 (20) | |
| Conditioning regimen, % | MAC | 6 (32) | 10 (33) |
| RIC | 13 (68) | 20 (67) | |
| Donor type, % | MRD | 8 (42) | 9 (30) |
| MUD | 9 (47) | 19 (63) | |
| MMUD | 2 (11) | 2 (7) | |
| GVHD prophylaxis, % | Tac-MTX | 11 (57) | 11 (37) |
| Tac-Sir | 3 (16) | 2 (7) | |
| Tac-Sir-MTX | 3 (16) | 13 (43) | |
| Others | 4 (21) | 4 (13) | |
| Characteristics . | No cGVHD, n = 19 . | cGVHD, n = 30 . | |
|---|---|---|---|
| Age at transplant, y | Medium | 51 | 60 |
| Range | 21-69 | 29-71 | |
| Sex, % | F | 12 (63) | 13 (43) |
| M | 7 (37) | 17 (57) | |
| Disease, % | AML/MDS | 12 (63) | 24 (80) |
| Others | 7 (37) | 6 (20) | |
| Conditioning regimen, % | MAC | 6 (32) | 10 (33) |
| RIC | 13 (68) | 20 (67) | |
| Donor type, % | MRD | 8 (42) | 9 (30) |
| MUD | 9 (47) | 19 (63) | |
| MMUD | 2 (11) | 2 (7) | |
| GVHD prophylaxis, % | Tac-MTX | 11 (57) | 11 (37) |
| Tac-Sir | 3 (16) | 2 (7) | |
| Tac-Sir-MTX | 3 (16) | 13 (43) | |
| Others | 4 (21) | 4 (13) | |
Abbreviations are explained in Table 1.